Since atopic dermatitis is less responsive to the current therapeutic approach, our observations highlight the role of Tpl2/ERK1/2 signaling pathway as a promising therapeutic target in canine skin inflammation, such as atopic dermatitis. The gene discussed is MAPK3; the disease is atopic eczema.